Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Zhaoke Ophthalmology Ltd. ( (HK:6622) ) is now available.
Zhaoke Ophthalmology Limited announced that the National Medical Products Administration of China has accepted its New Drug Application for the CsA Ophthalmic Gel, a treatment for moderate to severe dry eye disease. The gel, which is a proprietary hydrogel formulation, offers improved pharmacokinetic profiles and patient compliance due to its once-daily application and rapid onset of action. This acceptance marks a significant step for the company in enhancing its market position in the ophthalmic industry.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company incorporated in the British Virgin Islands and continued in the Cayman Islands, focusing on the development of innovative ophthalmic products. The company specializes in treatments for eye diseases, with a particular emphasis on products like the CsA Ophthalmic Gel, which targets moderate to severe dry eye disease.
Average Trading Volume: 2,590,007
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.18B
For a thorough assessment of 6622 stock, go to TipRanks’ Stock Analysis page.